Gene Editing and CRISPR: 3 Ways We Are Rewriting the Human Genome Right Now — And the 3 Questions No One Is Asking

By Dr. Narayan Rout | Author | Researcher |  ·  Science & Technology – Next Human Series  ·  50 min read  ·  Published: June 10, 2026

In This Research Pillar

Table of Contents

1. Introduction
2. What CRISPR Actually Is — The Molecular Scissors That Won the Nobel Prize
   1. How CRISPR Works — The Three-Step Mechanism
3. Way 1: Treating Inherited Genetic Diseases — From Casgevy to Personalised Medicine
   1. Baby KJ — The Most Personal Medicine in History
4. Way 2: Engineering Cancer Immunotherapy — Teaching the Immune System to Fight
   1. CRISPR and CAR-T Cell Therapy
5. Way 3: Germline Editing — The Heritable Rewriting That Is Banned but Has Already Happened
   1. The Governance Response — And Its Limits
6. The 3 Questions No One Is Asking
   1. Question 1: Who Defines a Genetic Defect?
   2. Question 2: Who Can Afford It?
   3. Question 3: What Does the Indian Philosophical Tradition Say?
7. The Quest Sage Insight
8. What You Can Do With This
9. Conclusion: The Most Powerful Tool Medicine Has Ever Had — And the Wisdom It Still Needs
10. Frequently Asked Questions: Gene Editing and CRISPR
11. References and Sources
12. Further Reading

In May 2025, a baby named KJ was discharged from Children’s Hospital of Philadelphia after 307 days as an inpatient. He had arrived as a newborn with a rare and dangerous metabolic disease — CPS1 deficiency — that prevents the liver from processing protein and causes toxic ammonia to build up in the blood. Without intervention, only about half the babies with his condition survive long enough to receive a liver transplant.

KJ did not receive a liver transplant. He received something that had never been done before: a CRISPR gene-editing therapy designed specifically for his unique genetic mutation, manufactured from scratch in just six months, and delivered directly into his liver cells through an intravenous infusion. The therapy corrected a single DNA letter — one base pair out of the three billion that constitute the human genome — and it worked. Within seven weeks of the first infusion, KJ was tolerating more dietary protein and requiring half his starting medication dose.

This case, published in the New England Journal of Medicine on May 15, 2025, is a landmark moment in human history. Not merely in medicine — in history. For the first time, a therapy was designed for a single individual’s unique genetic mutation, manufactured in months rather than years, and used to correct a specific error in the genetic code of a living human being. The era of personalised genome medicine has begun.

But the same month that Baby KJ went home, He Jiankui — the Chinese scientist who created the world’s first germline-edited human beings in 2018 by editing the genomes of embryos that resulted in the births of three children — had already served his three-year prison sentence and been released. The genie of human germline editing had already been released from its bottle. What remains is governance.

CRISPR is not a future technology. It is a present one — with an FDA-approved medicine, hundreds of active clinical trials, and a world’s first personalised therapy already documented and published. This article examines three ways it is rewriting the human genome right now, and three questions that the speed of its development has so far outrun.

CRISPR-Cas9 did not originate in a laboratory. It originated in bacteria — the oldest and most resilient forms of life on earth. Bacteria have been fighting viruses for billions of years, and over that time they evolved an adaptive immune system: when a virus attacks a bacterium, the bacterium can capture a fragment of the virus’s genetic code and store it in a special region of its own genome called the CRISPR array. If the same virus attacks again, the bacterium transcribes the stored sequence into a guide RNA that leads the Cas9 protein — a molecular cutting enzyme — directly to the viral DNA and slices it apart, neutralising the infection.

In 2012, Jennifer Doudna at UC Berkeley and Emmanuelle Charpentier at the Max Planck Institute realised that this bacterial immune system could be reprogrammed. Change the guide RNA — the sequence that tells Cas9 where to cut — and you can direct the molecular scissors to cut any DNA sequence in any organism. They published their proof of concept in Science (Doudna and Charpentier, Science 2012, DOI: 10.1126/science.1225829). They received the Nobel Prize in Chemistry in 2020.

The revolutionary implication was immediately recognised by the scientific community: CRISPR is fast, cheap, precise, and programmable. Previous gene-editing tools — zinc-finger nucleases and TALENs — could achieve similar effects but required laborious protein engineering for each new target and cost tens of thousands of dollars per experiment. CRISPR requires only changing the guide RNA sequence — a straightforward molecular biology procedure costing a few hundred dollars. The result was an explosion of research that has produced, in little over a decade, the world’s first approved gene therapy using this technology and hundreds of active clinical trials across disease areas that were previously considered incurable.

Step 1: A guide RNA (gRNA) is designed to match the target DNA sequence — the specific stretch of genome to be edited. This is the programmable element: changing the gRNA sequence changes the target. Step 2: The gRNA-Cas9 complex searches through the genome until it finds the matching sequence. Cas9 makes a double-strand cut — breaking both strands of the DNA double helix — at the precise location. Step 3: The cell’s own DNA repair mechanisms activate. Scientists exploit two of these mechanisms: non-homologous end joining (NHEJ), which typically disrupts the cut gene (useful for knocking out a gene); and homology-directed repair (HDR), which uses a provided template to make a precise edit (useful for correcting a mutation or inserting a new sequence).

Next-generation tools build on this mechanism with greater precision. Base editing — the technology used for Baby KJ’s personalised therapy and for Beam Therapeutics’ sickle cell trial — makes single-letter DNA corrections without creating a double-strand break, significantly reducing off-target effects and safety risks. Prime editing, described by its developers as the ‘search-and-replace’ of the genome, can make any point mutation, insertion, or deletion without a double-strand break or a donor DNA template. These advances are progressively reducing the risks while expanding the precision and range of what CRISPR-based approaches can achieve.

The FDA approval of Casgevy in December 2023 is correctly described as a milestone in medical history. For sickle cell disease — a genetic disorder affecting approximately 100,000 Americans and 20 million carriers in India alone — the therapeutic options before Casgevy were pain management, blood transfusions, and for a minority of patients, bone marrow transplantation. A one-time treatment that eliminates the debilitating crises of sickle cell disease by editing the patient’s own stem cells represents something genuinely new in medicine: a cure for a genetic disease at the molecular level.

The mechanism is elegant. Sickle cell disease is caused by a mutation in the HBB gene that produces an abnormal haemoglobin, causing red blood cells to collapse into a rigid sickle shape that blocks blood vessels and causes severe pain crises, organ damage, and shortened lifespan. Casgevy does not correct the HBB mutation directly. Instead, it uses CRISPR to reactivate the production of fetal haemoglobin (HbF) — the form of haemoglobin the body produces before birth, which does not sickle, and which is normally silenced after birth. With HbF restored to high levels, the sickling is prevented even though the HBB mutation remains.

The case of KJ Muldoon, published in the New England Journal of Medicine in May 2025, represents a different paradigm shift. Casgevy is a standardised therapy — the same product for all eligible patients with sickle cell disease. Baby KJ’s therapy was designed for a single patient’s unique mutation in the CPS1 gene — a gene encoding a liver enzyme essential for ammonia metabolism. The mutation was specific to KJ; no pre-existing therapy existed for it.

The team at CHOP and Penn, led by Kiran Musunuru and Rebecca Ahrens-Nicklas, used a base editor — a next-generation CRISPR tool that corrects a single DNA letter without creating a double-strand break — to correct the specific mutation in KJ’s CPS1 gene. The editor was delivered to liver cells via lipid nanoparticles (the same delivery technology used in COVID-19 mRNA vaccines) administered intravenously — no extraction of cells, no bone marrow conditioning, no transplantation. The therapy was designed, tested in cell models and mice, manufactured, and administered in just six months.

The implications of this case extend far beyond CPS1 deficiency. The technology platform is reusable. The base editor components are standardised; only the guide RNA sequence — which directs the editor to the specific target — needs to be customised per patient. KJ’s case demonstrates that CRISPR can deliver personalised genetic medicine for rare diseases — the 7,000+ rare genetic diseases that collectively affect 300 million people globally, most of which currently have no approved therapy — in clinically relevant timeframes and without requiring hospitalisation for cell extraction and transplantation.

For the genetics and neuroscience of consciousness and the broader questions about what DNA and the genome mean for human identity, see The Genetics of Consciousness: 5 Things DNA and Darshan Both Say About Who We Are (TheQuestSage.com).

Cancer is not one disease. It is hundreds of diseases, each defined by a specific pattern of genetic mutations in a specific cell type, with a unique combination of surface markers, growth drivers, and immune evasion mechanisms. The promise of CRISPR for cancer is the promise of molecular precision: the ability to engineer therapies targeted to the specific genetic characteristics of each patient’s tumour rather than using chemotherapy that indiscriminately attacks all rapidly dividing cells.

CAR-T cell therapy — chimeric antigen receptor T-cell therapy — is one of the most significant immunotherapy advances of the past decade. It involves extracting the patient’s T cells, engineering them in the laboratory to express a receptor that recognises cancer cells, and reinfusing them. CAR-T therapies have produced remarkable remissions in some haematological cancers — leukaemia and lymphoma — that had been refractory to all other treatments.

CRISPR enhances CAR-T therapy through multiple mechanisms. Knocking out PD-1 and CTLA-4 checkpoint genes in engineered T cells prevents tumour microenvironment suppression — removing the molecular brakes that tumours exploit to escape immune attack. Engineering allogeneic (donor-derived, universal) CAR-T cells through CRISPR-mediated HLA matching elimination allows off-the-shelf manufacturing rather than patient-specific production, making the therapy faster and potentially cheaper. Genome-wide CRISPR screening — systematically disrupting every gene in cancer cells to identify which genes are essential for survival — identifies new therapeutic targets that conventional approaches would have missed.

Multiple CRISPR-enhanced CAR-T and CAR-NK cell trials are in Phase I and II stages for haematological malignancies. The extension to solid tumours — which have been far more resistant to immunotherapy — is an active research frontier. The 239 active gene-editing clinical trials documented by CRISPR Medicine News in 2024 span this landscape.

The He Jiankui affair is the most important single event in the history of CRISPR ethics — not because He Jiankui succeeded in a scientific sense (the medical justification for his intervention was essentially non-existent) but because he demonstrated irrevocably that human germline editing is technically possible and that the governance frameworks in place in 2018 were insufficient to prevent a determined scientist from using it outside any ethical oversight structure.

He Jiankui edited the CCR5 gene in embryos that were subsequently implanted in women, resulting in the births of twin girls — Lulu and Nana — and later a third child. CCR5 is a co-receptor that HIV uses to enter T cells; people with a naturally occurring CCR5 deletion variant are resistant to certain strains of HIV. He claimed his edit was medically justified because the children’s fathers were HIV-positive — despite the fact that sperm-washing, a well-established and much simpler technique, reduces HIV transmission risk to less than 1%. The medical justification for creating heritable changes in three human genomes and all their future descendants was, in the judgment of the international scientific community, essentially zero.

The international response was swift and near-unanimous: condemnation. The WHO’s Expert Advisory Committee stated in 2019 that it was irresponsible for anyone to proceed with human germline genome editing. Eighteen leading scientists called for a moratorium. The Third International Summit on Human Genome Editing reaffirmed in 2023 that human germline editing is not acceptable since safety, ethical, and governance standards have not been met. Germline editing is banned in China, India, Brazil, Singapore, and many other countries.

But the governance response has a structural limitation that is rarely acknowledged: international scientific consensus is not the same as international law. There is no treaty, no binding international legal instrument, that prohibits human germline editing. What exists is a patchwork of national regulations with varying levels of enforcement — and the demonstration, by He Jiankui, that a scientist motivated to proceed and working in a jurisdiction with inadequate oversight can do so without prior detection. The genie has been released. The governance question is not whether it can be put back. It is how to ensure that the next application of germline editing — if and when it occurs — does so within a framework of scientific rigour, ethical review, public deliberation, and equitable access rather than the unilateral action of a single scientist with access to CRISPR equipment.

The therapy-enhancement distinction that underpins current CRISPR ethics assumes a clear answer to the question: which genetic variants are defects that should be corrected, and which are part of the normal range of human genetic diversity? For sickle cell disease, the answer seems clear — a mutation that causes severe pain crises, organ damage, and shortened life is a defect. For CPS1 deficiency, which threatens life in infancy, the answer is equally clear.

But the clarity dissolves rapidly as the range of potential CRISPR applications expands. In 2023, the Deaf community and disability rights advocates raised significant objections to proposals to use CRISPR to prevent genetic deafness — pointing out that the Deaf community does not widely regard deafness as a defect but as a different way of being human with its own language, culture, and community. The framing of CRISPR as a tool to ‘fix’ deafness assumes a definition of normal hearing that the Deaf community has specifically rejected. Similar arguments apply to certain autism spectrum conditions, to Down syndrome advocacy communities, and potentially — as genetic associations with psychological traits become better understood — to genetic variants associated with introversion, with unconventional cognition, or with psychological states that contemporary society labels as disorders.

The eugenic impulse — the drive to eliminate what is defined as genetically inferior in order to produce a ‘better’ human stock — does not require a formal government programme. It requires only a technology that can eliminate genetic variants, a definition of which variants are undesirable, and a social context in which genetic testing and editing become normal features of reproduction. The current trajectory of CRISPR development, without explicit governance frameworks that address the definition-of-defect problem, risks reproducing the logic of eugenics through private medical decision-making rather than state compulsion.

The $2.2 million price tag of Casgevy is the most direct statement of the access problem. Sickle cell disease is not a disease of the wealthy. It is a disease disproportionately affecting people of African, South Asian, Middle Eastern, and Mediterranean descent — communities whose global distribution skews toward low and middle-income countries. India’s sickle cell disease burden — approximately 20 million carriers, with approximately 12,000-15,000 affected births annually — is among the world’s highest. The Indian government’s Sickle Cell Anaemia Mission aims to screen and provide basic support but has no realistic pathway to providing $2.2 million therapies at scale.

The access problem is not unique to CRISPR — it characterises pharmaceutical innovation broadly. But it is particularly acute for CRISPR because the technology’s promise is explicitly universal: CRISPR’s advocates describe it as a tool that will eliminate heritable diseases. If that elimination is available only to patients in countries wealthy enough to reimburse a $2.2 million therapy, the promise is not universal — it is a promise to the wealthy with the implication that the heritable disease burden will become increasingly concentrated in the populations that cannot afford the cure. This would represent a new dimension of global health inequity built on a technology that was initially celebrated for its democratic accessibility.

The dominant framework for CRISPR ethics is Western bioethics: individual autonomy, informed consent, risk-benefit analysis, and procedural governance. This framework has produced important safeguards and will continue to be necessary. But it is insufficient — because it does not have the philosophical vocabulary to address the most profound question raised by germline editing: the question of the authority to make permanent, heritable changes to the genetic substrate of future human beings who cannot consent and whose existence depends on the decisions being made.

अहं ब्रह्मास्मि — तत् त्वम् असि |
I am Brahman. That thou art. The individual self is not separate from the universal. The genome is not merely individual property — it is a localised expression of universal intelligence.

– Brihadaranyaka Upanishad 1.4.10 and Chandogya Upanishad 6.8.7

The Panchamahabhuta framework — the understanding that the body is constituted from five universal elements (earth, water, fire, air, and space) that are not the individual’s property but expressions of universal principles — raises a question that Western bioethics does not: if the genome is a localised expression of universal intelligence operating through the five elements, what is the ethical standing of the decision to permanently alter it? Who has the authority to permanently rewrite what the universe, through billions of years of evolutionary intelligence, has written?

The Karma-Sanskara framework adds a further dimension. Karma — the law of action and consequence — and Sanskara — the inscribed impressions that shape future manifestation — together describe a principle in which what has been done becomes the substrate of what comes next. Germline editing creates a Sanskara in the genome of future generations — an inscription made before their birth that they cannot alter and did not choose. The ethical question of consent, which Western bioethics addresses procedurally, is addressed philosophically in the Indian tradition through the concept of Dharma: the rightness of action in accordance with the nature of things. Is it Dharmic to inscribe a choice into the genome of beings who will not exist until after the choice has been made?

These are not questions with simple answers. They are questions whose depth the Western bioethics framework does not fully capture — and whose exploration the speed of CRISPR development has not waited for.

want to offer a perspective on the CRISPR conversation that goes beyond the science and the ethics as usually framed.

We are in the early decades of humanity’s first genuinely transformative capability to edit its own biological code. The human genome — three billion base pairs, encoding approximately 20,000 genes, shaped by four billion years of evolutionary history — is not primarily a medical record of defects to be corrected. It is, in the deepest sense, the biological expression of what the universe has learned about how to build a conscious being. Every genetic variant that has persisted in the human population has persisted because, at some point in some environment, it conferred some advantage or at minimum did not impose sufficient disadvantage to be eliminated. The HbS mutation that causes sickle cell disease persists in malaria-endemic populations because the heterozygous carrier state — one copy of the mutation — confers significant malaria resistance. The genetic variants associated with certain psychological intensities may confer creative or perceptual capacities alongside their vulnerabilities.

None of this means that CRISPR should not be used to treat sickle cell disease. Baby KJ’s successful personalised therapy is one of the most beautiful stories in the history of medicine — a team of dedicated scientists and clinicians devoting themselves to saving one child’s life with the most sophisticated molecular tools humanity has ever produced. The goodness of that act is not diminished by the complexity of the questions the same technology raises in other contexts.

What I am suggesting is that the Vedic framework’s understanding of the body as sacred matter — not sacred in a superstitious sense but in the sense of being the product of intelligence that exceeds individual human comprehension — offers a useful caution against the hubris that CRISPR’s power invites. The ability to edit the genome does not automatically confer the wisdom to know which edits are improvements. The track record of human technology in other domains — nuclear energy, industrial agriculture, social media algorithms — suggests that the capacity to do something and the wisdom to know whether it should be done are not the same capacity, and do not develop at the same pace.

The three questions no one is asking — who defines a defect, who can afford the cure, and what civilisational frameworks provide the ethical architecture — are not obstacles to CRISPR’s therapeutic development. They are the conditions that would make that development genuinely beneficial rather than merely technically impressive. The difference between medicine and enhancement, between equity and privilege, between wisdom and power — these are the questions that the speed of CRISPR development must somehow find time for.

• Understand the somatic versus germline distinction before forming an opinion on CRISPR ethics. Somatic editing for serious genetic disease — treating a patient’s own cells, affecting only that patient — is broadly supported by the scientific community and has produced the first approved gene therapy. Germline editing — making heritable changes to embryos — is currently banned or under moratorium in most countries including India. These are not the same thing. Most CRISPR development happening now is somatic. Most CRISPR concern expressed in popular discourse conflates somatic therapy with germline enhancement. The distinction matters.
• For Indians with genetic disease burden in the family — explore what is coming. India has significant sickle cell disease, thalassemia, and other monogenic disease burdens. The CRISPR therapies that are FDA-approved or in clinical trials now may become accessible in India in the next decade. The Danaher-IGI Beacon for CRISPR Cures explicitly focuses on affordable manufacturing and global accessibility. The Indian government’s Sickle Cell Mission is a relevant policy context. Understanding what is coming is the prerequisite for advocating for equitable access.
• Engage with the philosophical questions — not just the scientific ones. The CRISPR conversation in India tends to be dominated by either uncritical enthusiasm for the technology or blanket rejection on religious grounds. Both responses miss the genuine complexity. The Panchamahabhuta and Karma-Sanskara frameworks are not obstacles to understanding CRISPR — they are resources for thinking about it with more depth than the Western bioethics framework alone provides. What does it mean to be the kind of being whose genome can be edited? That is a question worth sitting with.
• Follow the Baby KJ story as a benchmark for personalised medicine. The technology platform demonstrated by KJ’s case — base editing delivered by lipid nanoparticles, designed to a specific patient’s unique mutation in 6 months — is a platform with implications far beyond CPS1 deficiency. The team at CHOP and Penn explicitly stated that this platform can be extended to hundreds of rare diseases. Following the scientific and regulatory development of this platform over the next 5-10 years will tell you more about the future of medicine than almost any other single story to watch.

Three things are happening simultaneously in CRISPR medicine right now. Casgevy is treating sickle cell disease patients at 50 active centres across three continents, offering clinical cure to people who previously had no option beyond managing their pain. Baby KJ is home after the first personalised CRISPR therapy, demonstrating that a technology platform for rare genetic diseases can be designed and delivered in months rather than decades. And 239 active clinical trials are exploring applications from cancer immunotherapy to cholesterol reduction to chronic hepatitis B.

At the same time: Casgevy costs $2.2 million per patient, placing it beyond reach for the vast majority of the world’s sickle cell disease population. He Jiankui’s three germline-edited children are growing up somewhere in China with changes to their DNA — and their descendants’ DNA — that no governance framework prevented and that no international agreement can reverse. And the question of who defines genetic normalcy and its deviations — the foundational question that determines how far CRISPR editing should go — has no agreed answer.

The technology is not waiting for the ethics. It never does. What the Indian philosophical tradition offers — the Panchamahabhuta’s understanding of the body as sacred matter, the Karma-Sanskara framework for evaluating the authority to make permanent inscriptions in future genomes, the Advaita insight that the individual genome is a localised expression of universal intelligence — is not a reason to stop CRISPR development. It is a reason to develop it with the depth of reflection that its power demands.

We are rewriting the human genome. The question is whether we are rewriting it wisely.

1. Doudna, J.A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816–821. DOI: 10.1126/science.1225829. Nobel Prize in Chemistry 2020.

2. FDA. (2023, December 8). FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. FDA Press Announcement. Casgevy: first FDA-approved CRISPR/Cas9 therapy; CRISPR/Cas9 cuts DNA at targeted areas; edited stem cells increase fetal haemoglobin. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease

3. CRISPR Therapeutics IR. (2024, March 30). Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY for Sickle Cell Disease. ~16,000 eligible patients 12+; US $200 million milestone payment; 50 active treatment sites by early 2026. https://ir.crisprtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval

4. Musunuru, K., Ahrens-Nicklas, R., et al. (2025, May 15). Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. New England Journal of Medicine. DOI: 10.1056/NEJMoa2504747. Baby KJ; CPS1 deficiency; base editing; lipid nanoparticle delivery; 6-month development; first personalised CRISPR therapy; CHOP/Penn.

5. IGI. (2026, March 23). CRISPR Clinical Trials: A 2025 Update. Innovative Genomics Institute. Casgevy as first CRISPR medicine; Beam Therapeutics BEACON trial base editing; 50 active Casgevy sites; Baby KJ first personalised CRISPR therapy. https://innovativegenomics.org/news/crispr-clinical-trials-2025/

6. NIH. (2025, May 23). Infant with rare, incurable disease is first to successfully receive personalized gene therapy treatment. CHOP and Penn team; Musunuru and Ahrens-Nicklas; CPS1 correction; LNP delivery; 307 days in hospital; discharged June 2025. https://www.nih.gov/news-events/news-releases/infant-rare-incurable-disease-first-successfully-receive-personalized-gene-therapy-treatment

7. Inside Precision Medicine. (2025, August 15). First Personalized CRISPR Gene Editing Therapy Patient Baby KJ Discharged. Danaher-IGI Beacon for CRISPR Cures; scalable delivery; affordable manufacturing; global accessibility goal. https://www.insideprecisionmedicine.com/topics/precision-medicine/first-personalized-crispr-gene-editing-therapy-patient-baby-kj-discharged/

8. CRISPR Medicine News. (2024, December). CRISPR Medicine in 2024: A Recap. 239 active gene-editing trials; Casgevy approvals (UK, FDA, EMA, Saudi Arabia, Canada); hereditary amyloidosis and hereditary angioedema Phase 3 trials; TUNE-401 for hepatitis B; next-generation delivery systems. https://crisprmedicinenews.com/news/crispr-medicine-in-2024-a-recap/

9. Pavani, G., & Guiraud, S. (2024, May 8). CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments. Cells, 13(10), 800. DOI: 10.3390/cells13100800. PMC: PMC11119143. CRISPR modification of haematopoietic stem cells; blood disorders; cancer; off-target effects; delivery systems.

10. PMC. (2025). Gene Editing: Developments, Ethical Considerations, and Future Directions. PMC11759082. He Jiankui timeline; moratorium calls; NIH position; Third International Summit 2023 reaffirmation; somatic vs germline distinction.

11. IntechOpen. (2025, September 30). Editing the Future: Ethical Challenges of Therapeutic Use, Germline Modification and Human Enhancement with CRISPR. Off-target effects; informed consent; designer babies; germline bans — Brazil, China, India, Singapore, Uganda; enhancement vs correction debate.

12. IGI. (2025, January 21). CRISPR & Ethics. He Jiankui affair; CCR5 edit; twin girls and third child; international condemnation; three years prison; governance response; enhancement concerns. https://innovativegenomics.org/crisprpedia/crispr-ethics/

13. Springer HEC Forum. (2024, September 20). The Ethics of Human Embryo Editing via CRISPR-Cas9: A Systematic Review. DOI: 10.1007/s10730-024-09538-1. Six major themes: risk/harm; benefit; oversight; informed consent; justice/equity; eugenics.

14. ResearchGate. (2025, October 30). Key ethical concerns surrounding CRISPR-Cas9 in human genome editing and policy responses. He Jiankui case study; WHO Expert Advisory Committee 2019; global governance; public benefit priority.

15. Asamaka Industries. (2026, January 26). CRISPR and Human Ethics of Gene Editing. Conservative debate on germline; safety and benefit evidence requirements; CHOP/Penn personalised therapy as ethical model; equal accessibility as governance goal.

16. Taittiriya Upanishad, Shiksha Valli; Panchamahabhuta — five elements as constituents of the body. Body as expression of universal principles, not individual property.

17. Brihadaranyaka Upanishad 1.4.10. Aham Brahmasmi — I am Brahman. Individual self as expression of universal consciousness; genome as localised expression of universal intelligence.

18. Chandogya Upanishad 6.8.7. Tat Tvam Asi — That Thou Art. The identity of individual and universal; ethical implications for heritable modification.

19. Yoga Sutras of Patanjali. Prakriti-Purusha distinction. Matter (including the genome) and consciousness (the observer); the relationship between biological substrate and the witnessing awareness that inhabits it.

20. Narayan Rout. Yogic Intelligence vs Artificial Intelligence. BFC Publications, 2025. (The inner intelligence that genome editing cannot replicate — Prajna versus the technical intelligence of Vijnana.)

P10 The Next Human — Science, Technology & Human Evolution

• The Genetics of Consciousness: 5 Things DNA and Darshan Both Say About Who We Are (TheQuestSage.com) — The Orch OR theory, the hard problem of consciousness, and what the genome encodes beyond biology.
• The Road to Super AI: 3 Scenarios That Keep the World’s Smartest People Awake at Night (TheQuestSage.com) — The parallel convergence of AI and CRISPR as the two technologies most likely to reshape humanity.
• Yogic Intelligence vs Artificial Intelligence (TheQuestSage.com) — The intelligence that cannot be edited into a genome — Prajna and the inner development of consciousness.
• Advaita Vedanta and Modern Science: 5 Remarkable Convergences (TheQuestSage.com) — The Aham Brahmasmi framework that contextualises the authority to edit the genome.

---